Targeted portfolio

An experienced team of professionals from the generics and brand industry has built a strong profitable base and infrastructure for our generic and brand business in the U.S..

Product formulations manufactured and sold by Alvogen include solid oral dose, tab-in-tab tablets, modified release tablets, soft gelatin capsules, powder capsules, bead capsules, oral suspension, oral thin film, transdermals, creams, ointments, and injectables – both pen and vial.

Almaject® Inc. is a wholly owned subsidiary of Alvogen, specializing in the commercialization of generic injectable pharmaceuticals for the acute and alternate site healthcare markets in the US.

Alvogen currently has an extensive OTC (over-the-counter) portfolio, offering an innovative approach to everyday health problems. Our range covers the main OTC categories: Food supplements, OTC medicines, cosmetics and medical devices.

We seek out products that offer something new to the consumer, focusing on patented technology with clinically proven efficacy, along with staple OTC products necessary in every household, such as painkillers, antihistamines and ointments. Our OTC strategy centers around comprehensive solutions based on unique target market segmentation and value added properties, such as taste, delivery form or ingredient composition.

Alvogen is focused on the acquisition, development and commercialization of brand named Rx products through its subsidary Almatica Pharma. Almatica has a current product portfolio that includes pain, anti-infective, cardiovascular and psychiatry related therapies.

Our business model ensures competitive advantage by having broad in-house capabilities and a network of partners for enhanced speed and flexibility.